Polysubstance Use Disorders Among US Adults

Why It Matters

The findings highlight that early substance exposure fuels complex addiction patterns, demanding integrated prevention and treatment strategies to curb escalating health and economic burdens.

Key Takeaways

• Over 4% of adults have two substance use disorders.
• More than 1.5% have three or more concurrent SUDs.
• Early initiation (<18) raises odds of ≥4 substance use to 17%.
• Opioid misusers show 53% prevalence of using ≥4 substances.
• Nicotine dependence co‑occurs with other SUDs in 62% of cases.

Pulse Analysis

Polysubstance use disorders (PSUDs) have emerged as a critical public‑health challenge, reflecting overlapping neurobiological pathways that amplify dopamine signaling across diverse drugs. While alcohol use disorder has modestly declined, recent years have seen sharp rises in cannabis, methamphetamine, and especially opioid misuse, creating a landscape where individuals frequently combine multiple substances. This convergence complicates diagnosis, treatment adherence, and mortality risk, prompting researchers to reassess prevalence using up‑to‑date, nationally representative data.

The 2022‑2023 NSDUH analysis provides a granular snapshot of PSUDs among U.S. adults. Approximately 76% reported no SUD, yet 4.6% carried two, and 1.6% carried three or more concurrent disorders. Notably, among those misusing opioids, more than half (53%) used four or more substances in the past year. Early initiation proved a powerful predictor: adults who first used any substance before age 18 were 7‑fold more likely to use four or more substances (16.9% vs. 2.3% for later starters). Similar spikes appeared for alcohol, nicotine, and cannabis initiators, underscoring adolescence as a vulnerable window for lifelong poly‑use trajectories.

These insights compel a shift toward integrated screening and treatment models that address the full spectrum of substance use rather than isolated disorders. Policymakers should prioritize early‑life prevention programs, expand access to comprehensive addiction services, and incorporate nicotine dependence into PSUD frameworks. Clinicians must adopt multimodal interventions—combining medication‑assisted therapy, behavioral counseling, and social support—to mitigate the compounded risks of poly‑use. Continued surveillance and research will be essential to track evolving patterns and evaluate the impact of coordinated public‑health responses.